2023-12-01 08:19:06
Forty years following the discovery of HIV, many battles have been won, and many hopes disappointed. Overview of the avenues explored by research to put an end to AIDS.
Will it be possible to end HIV by 2030, as the UNAIDS association aims for? Forty years of research on HIV have made it possible to advance, particularly on triple therapy treatments, which prevent the last phase of the infection called AIDS, then more recently on Prep, a preventive treatment which prevents infection in the event of exposure. But there is still a long way to go to truly overcome the disease. “We continue to be interested in the replication of the virus and in understanding how certain carriers escape the pathology of the virus. HIV. It is hoped that this work will resolve certain aspects of the infection, particularly in the face of failure of vaccine in recent years», declares Christophe d’Enfert, scientific director of the Pasteur Institute, which is hosting 3 days of conferences on HIV from November 29 to December 1. Where is the basic, clinical and social research work? Le Figaro make the point.
Prevent the virus from entering cells
Faced with HIV, the body’s cells defend themselves using proteins that “fight the virus by inhibiting its fusion with the host cell,” explains Michaela Müller-Trutwin, head of the HIV, inflammation and persistence unit at the Institut Pasteur and president of the coordinated action on basic and translational HIV research for the ANRS MIE. “These proteins work once morest several viruses, such as Sars-CoV-2 and HIV.» Research on these proteins will perhaps make it possible to develop drugs to limit the ability of HIV to fuse with cells, therefore to release its genetic heritage and infect the entire body.
» READ ALSO – The molecule that protects once morest AIDS identified
Stop the virus from replicating in cells
HIV is a so-called “RNA” virus: its genetic heritage is carried by ribonucleic acid, a molecule very close chemically to DNA (deoxyribonucleic acid). When HIV target cells (TCD4 lymphocytes and macrophages) are infected, the virus’s RNA is “reverse transcribed” into DNA, which allows the virus to use the cellular machinery to replicate. We have recently known that this step takes place in the cell nucleus, a “RNA replication factory», comments Michaela Müller-Trutwin. A field of research is therefore opening up on this very particular stage of a viral infection: preventing retrotranscription directly in the nuclei of infected cells would make it possible to block HIV replication.
The gut microbiota plays a role in infection
A large number of infected cells lodge in the intestine. However, it contains a population of microorganisms, the intestinal microbiota, probably involved in HIV infection. “We suspect the microbiota of having a role but it is difficult to understand it. recalls Asier Sáez-Cirión, director and head of the viral reservoirs and immune control unit at the Pasteur Institute and president of the Sidaction scientific and medical committee. “We know that there is clearly an impact of compounds produced by bacteria. We know that the person’s metabolism will have an impact on the reservoirs, but the link is not clearly established. Experiments on mice with or without microbiota are underway to determine the role of the microbiota on virus acquisition and pathogenicity.”
» READ ALSO – AIDS: strange remission of a patient following a bone marrow transplant
Boost innate immunity to target HIV reservoirs
To defend itself, our body has two lines of cellular defense, innate immunity, rapid but not very specific, and adaptive immunity, slower because it requires the lymphocytes to mature, but more specific. Research focuses on rapid innate immunity cells, natural killer cells (or “NK”, for “natural killer”) which act quickly on infected cells and are capable of entering HIV reservoirs with difficulty. accessible through available treatments. The research aims to manufacture a vaccine capable of mobilizing these NK to prevent HIV infection and target the reservoirs. But Michaela Müller-Trutwin specifies that “ natural killer cells come into contact with these infected CD4 lymphocytes to kill them if they produce viruses, but they will not be able to recognize an infected cell that does not produce HIV “. The NK strategy will not be able to limit infections alone, but combined with triple therapy or future gene therapies, it might prove effective.
Gene therapy to eliminate viruses and reservoirs
Only five cases of complete recovery have been recorded in the world. These are always patients who have benefited from a marrow transplant (for another pathology). Apart from these exceptions, we rather speak of remission of HIV infection, that is to say that there may remain a little virus present in the body but that the level is controlled, with treatment by triple therapy. These treated patients now have undetectable levels of HIV in their blood and are no longer transmitting the virus, but they cannot completely get rid of it. HIV persists in host cells and organs called “reservoirs”, respectively macrophages and lymph nodes. Gene therapy trials are underway to try to make cells resistant to infection or prevent replication of the virus.
» READ ALSO – HIV-AIDS: a candidate treatment for lasting remission
Neutralizing antibodies
A team from Rockefeller Hospital in New York uses broad-spectrum neutralizing antibodies naturally produced by a few rare patients. Today, “30 people are in remission from HIV with this neutralizing antibody technique», Announces Asier Sáez-Cirión. However, Michaela Müller-Trutwin specifies that “we know how to make them in the laboratory but we don’t know how to induce their production in a patient.” Another limitation: a high concentration must be injected to be effective.
Vaccine research continues
The HIV virus mutates a lot, much more than the Covid virus, and many variants exist. The antigens present on its surface, which are targeted by the antibodies, therefore change a lot, which does not facilitate their identification. This variability currently prevents the manufacture of a vaccine that is effective on all existing viruses, testifies Michaela Müller-Trutwin. Many Phase I and II trials worked, but Phase III, which tests the true effectiveness of pharmaceuticals in large numbers of patients, failed. However, research on a messenger RNA vaccine once morest HIV has not been in vain: it has notably enabled the ultra-rapid development of the vaccine once morest Covid. Research for an AIDS vaccine is now turning to messenger RNA vaccines, capable of stimulating the production of neutralizing antibodies.
1701493253
#avenues #research #HIVAIDS
